You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity

 

Online download statistics by month:

Online download statistics by month: October 2020 to January 2026

AbstractFullPdf
Oct 202020120160
Nov 202017317297
Dec 202010910957
Jan 202111211246
Feb 2021676729
Mar 2021828235
Apr 202112512644
May 2021575721
Jun 2021595923
Jul 2021686827
Aug 2021737340
Sep 2021535318
Oct 2021656540
Nov 2021757542
Dec 2021494919
Jan 2022535422
Feb 202243449
Mar 2022687027
Apr 2022626216
May 2022636432
Jun 2022697224
Jul 2022626221
Aug 2022394225
Sep 2022535361
Oct 2022485027
Nov 2022414117
Dec 2022565614
Jan 2023272811
Feb 2023585812
Mar 2023363828
Apr 2023343622
May 2023424216
Jun 2023676950
Jul 2023373830
Aug 202328287
Sep 2023232311
Oct 2023373710
Nov 2023313311
Dec 2023333411
Jan 202418198
Feb 2024272721
Mar 2024303016
Apr 2024252514
May 20242202219
Jun 2024282817
Jul 2024464624
Aug 2024242311
Sep 2024191915
Oct 2024323227
Nov 2024282917
Dec 2024212120
Jan 2025414227
Feb 2025242417
Mar 2025434324
Apr 2025494925
May 2025363630
Jun 2025222222
Jan 2026220
Total321332401456